Stockholders' Equity

6 Months Ended

Jun. 30, 2013

Equity [Abstract]

Stockholders' Equity

NOTE 8 — STOCKHOLDERS’ EQUITY

(a) Stock Purchase Rights

All shares of the Company’s common stock, if issued prior to the termination by the Company of its rights agreement, dated as of December 4, 2006, include stock purchase rights. The rights are exercisable only if a person or group acquires twenty percent or more of the Company’s common stock or announces a tender or exchange offer which would result in ownership of twenty percent or more of the Company’s common stock. Following the acquisition of twenty percent or more of the Company’s common stock, the holders of the rights, other than the acquiring person or group, may purchase Medivation common stock at half of its fair market value. In the event of a merger or other acquisition of the Company, the holders of the rights, other than the acquiring person or group, may purchase shares of the acquiring entity at half of their fair market value. The rights were not exercisable at June 30, 2013.

(b) Medivation Equity Incentive Plan

The Medivation Equity Incentive Plan, which is stockholder-approved, provides for the issuance of options and other stock-based awards, including restricted stock units, performance share awards and stock appreciation rights. The Medivation Equity Incentive Plan is administered by the Board, or a committee appointed by the Board, which determines recipients and types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The vesting of all outstanding awards under the Medivation Equity Incentive Plan, including all outstanding options, restricted stock units, performance share awards and stock appreciation rights will accelerate, and all such share awards will become immediately exercisable, upon a “change of control” of Medivation, as defined in the Medivation Equity Incentive Plan.

On July 13, 2012, the Company’s stockholders approved an amendment and restatement of the Medivation Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the Medivation Equity Incentive Plan from 7,500,000 to 9,300,000. As a result of the two-for-one forward stock split described previously, the number of shares of common stock authorized for issuance under the Medivation Equity Incentive Plan was increased to 18,600,000 effective September 21, 2012. As a result of the stock split, the number of shares of the Company’s common stock issuable upon exercise of outstanding stock options and vesting of other stock-based awards was proportionally increased, and the exercise price per share thereof was proportionally decreased, in accordance with the terms of the Medivation Equity Incentive Plan.

On June 28, 2013, the Company’s stockholders approved an amendment and restatement of the Medivation Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the Medivation Equity Incentive Plan from 18,600,000 to 19,150,000.

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2013:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (1)
Outstanding at December 31, 2012		7,038,291		$	18.90
Granted		337,606		$	49.75
Exercised		(308,914	)	$	11.82
Forfeited		(18,104	)	$	35.56
Outstanding at June 30, 2013		7,048,879		$	20.65		6.95	$	205.8
Vested and exercisable at June 30, 2013		4,093,583		$	11.67		5.72	$	153.6

⁽¹⁾  The aggregate intrinsic value is calculated as the pre-tax difference between the weighted average exercise price of the underlying awards and the closing price per share of $49.20 of the Company’s common stock on June 28, 2013. The calculation excludes any awards with an exercise price higher than the closing price of the Company’s common stock on June 28, 2013. The amounts are presented in millions.

The weighted-average grant-date fair value per share of options granted during the six months ended June 30, 2013 was $30.57.

Restricted Stock Units

The following table summarizes restricted stock unit activity for the six months ended June 30, 2013:

	Number of Shares			Weighted- Average Grant-Date Fair Value
Unvested at December 31, 2012		373,625		$	39.06
Granted		73,993		$	50.94
Vested		—			—
Forfeited		(1,856	)	$	52.92
Unvested at June 30, 2013		445,762		$	40.98

Stock Appreciation Rights

The Company granted stock appreciation rights to certain employees pursuant to the terms of the Medivation Equity Incentive Plan. Stock appreciation rights give the holder the right, upon exercise, to receive the difference between the market price per share of the Company’s common stock at the time of exercise and the exercise price of the stock appreciation right. The exercise price of the stock appreciation right is equal to the market price of the Company’s common stock at the date of the grant. The stock appreciation rights are settlable in shares of the Company’s common stock.

The following table summarizes stock appreciation rights activity for the six months ended June 30, 2013:

	Number of Rights			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (1)
Outstanding at December 31, 2012		883,600		$	23.91
Granted		—			—
Exercised		(22,410	)	$	23.20
Forfeited		—			—
Outstanding at June 30, 2013		861,190		$	23.93		8.48	$	21.8
Vested and exercisable at June 30, 2013		294,790		$	23.97		8.47	$	7.4

⁽¹⁾  The aggregate intrinsic value is calculated as the pre-tax difference between the weighted average exercise price of the underlying awards and the closing price per share of $49.20 of the Company’s common stock on June 28, 2013. The calculation excludes any awards with an exercise price higher than the closing price of the Company’s common stock on June 28, 2013. The amounts are presented in millions.

Performance Share Awards

There were no outstanding performance share awards under the Medivation Equity Incentive Plan at either June 30, 2013 or December 31, 2012.

Warrants

At June 30, 2013, warrants to purchase an aggregate of 45,808 shares of Medivation common stock at a weighted-average exercise price of $3.46 per share were outstanding. These outstanding warrants expire between 2014 and 2017.

Stock-Based Compensation

The Company estimates the fair value of stock options and stock appreciation rights using the Black-Scholes valuation model, which requires the use of subjective assumptions related to the estimated stock price volatility, estimated term, estimated dividend yield and risk-free interest rate. The Black-Scholes assumptions used for stock options and stock appreciation rights granted were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,
	2013	2012	2013	2012
Risk-free interest rate	0.73-1.55%	0.83%	0.73-1.55%	0.83-1.01%
Estimated term (in years)	5.25-5.50	5.42	5.24-5.50	5.42-5.48
Estimated volatility	73-75%	71%	68-75%	71-73%
Estimated dividend yield	—	—	—	—

Stock-based compensation expense was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Stock-based compensation expense recognized as:
R&D expense	$	3,619	$	3,048	$	7,437	$	5,485
SG&A expense		4,512		2,533		8,990		4,432
Total	$	8,131	$	5,581	$	16,427	$	9,917

Unrecognized stock-based compensation expense totaled $77.2 million at June 30, 2013 and is expected to be recognized over a weighted-average period of 2.8 years.

(c) Medivation Employee Stock Purchase Plan

The Medivation, Inc. 2013 Employee Stock Purchase Plan, or ESPP, which was approved by the Company’s stockholders on June 28, 2013, permits eligible employees to purchase shares of the Company’s common stock through payroll deductions at the lower of 85% of the fair market value of the stock at the beginning or ending of a purchase period. Eligible employee contributions are limited on an annual basis to $25,000 in accordance with Section 423 of the Internal Revenue Code. The first purchase period under the plan will commence on October 1, 2013 and will conclude on March 31, 2014. As of June 30, 2013, a total of 3,000,000 shares of the Company’s common stock were authorized for issuance under the ESPP and no shares have been issued.